In a report, hypoxic and cytokine-inducible enhancers, both of which are active in some tumor environments, are combined with endothelial cell-specific E-selectin and VEGF receptor 2 promoters [95] to achieve a maximum possible tumor endothelium-specific transcription. This evidence concerns the gene SELE and neoplasm.